Cramer, P. Organization and regulation of gene transcription. Nature 573, 45–54 (2019).

CAS  Google Scholar 

Haberle, V. & Stark, A. Eukaryotic core promoters and the functional basis of transcription initiation. Nat. Rev. Mol. Cell Biol. 19, 621–637 (2018).

CAS  Google Scholar 

Lambert, S. A. et al. The human transcription factors. Cell 172, 650–665 (2018).

CAS  Google Scholar 

Allis, C. D. & Jenuwein, T. The molecular hallmarks of epigenetic control. Nat. Rev. Genet. 17, 487–500 (2016).

CAS  Google Scholar 

Millán-Zambrano, G., Burton, A., Bannister, A. J. & Schneider, R. Histone post-translational modifications-cause and consequence of genome function. Nat. Rev. Genet. 23, 563–580 (2022).

Google Scholar 

Feinberg, A. P. The key role of epigenetics in human disease prevention and mitigation. N. Engl. J. Med. 378, 1323–1334 (2018).

CAS  Google Scholar 

Chen, T. & Dent, S. Y. Chromatin modifiers and remodellers: regulators of cellular differentiation. Nat. Rev. Genet. 15, 93–106 (2014).

CAS  Google Scholar 

Waddington, C. H. The epigenotype. 1942. Int. J. Epidemiol. 41, 10–13 (2012).

CAS  Google Scholar 

Elsherbiny, A. & Dobreva, G. Epigenetic memory of cell fate commitment. Curr. Opin. Cell Biol. 69, 80–87 (2021).

CAS  Google Scholar 

Atlasi, Y. & Stunnenberg, H. G. The interplay of epigenetic marks during stem cell differentiation and development. Nat. Rev. Genet. 18, 643–658 (2017).

CAS  Google Scholar 

Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31–46 (2022).

CAS  Google Scholar 

Esteller, M. et al. The epigenetic hallmarks of cancer. Cancer Discov. 14, 1783–1809 (2024).

CAS  Google Scholar 

Falkenberg, K. J. & Johnstone, R. W. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug Discov. 13, 673–691 (2014).

CAS  Google Scholar 

Quintás-Cardama, A., Santos, F. P. & Garcia-Manero, G. Therapy with azanucleosides for myelodysplastic syndromes. Nat. Rev. Clin. Oncol. 7, 433–444 (2010).

Google Scholar 

Prager, B. C., Xie, Q., Bao, S. & Rich, J. N. Cancer stem cells: the architects of the tumor ecosystem. Cell Stem Cell 24, 41–53 (2019).

CAS  Google Scholar 

Batlle, E. & Clevers, H. Cancer stem cells revisited. Nat. Med. 23, 1124–1134 (2017).

CAS  Google Scholar 

Loh, J. J. & Ma, S. Hallmarks of cancer stemness. Cell Stem Cell 31, 617–639 (2024).

CAS  Google Scholar 

Galassi, C., Esteller, M., Vitale, I. & Galluzzi, L. Epigenetic control of immunoevasion in cancer stem cells. Trends Cancer 10, 1052–1071 (2024).

CAS  Google Scholar 

Galassi, C., Chan, T. A., Vitale, I. & Galluzzi, L. The hallmarks of cancer immune evasion. Cancer Cell 42, 1825–1863 (2024).

CAS  Google Scholar 

Hall, A. W. et al. Bivalent chromatin domains in glioblastoma reveal a subtype-specific signature of glioma stem cells. Cancer Res. 78, 2463–2474 (2018).

CAS  Google Scholar 

Easwaran, H. et al. A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res. 22, 837–849 (2012).

CAS  Google Scholar 

Somervaille, T. C. et al. Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell 4, 129–140 (2009).

CAS  Google Scholar 

Ben-Porath, I. et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet 40, 499–507 (2008).

CAS  Google Scholar 

Wainwright, E. N. & Scaffidi, P. Epigenetics and cancer stem cells: unleashing, hijacking, and restricting cellular plasticity. Trends Cancer 3, 372–386 (2017).

CAS  Google Scholar 

Chu, X. et al. Cancer stem cells: advances in knowledge and implications for cancer therapy. Signal Transduct. Target Ther. 9, 170 (2024).

CAS  Google Scholar 

Lee, E. J. et al. Identification of global DNA methylation signatures in glioblastoma-derived cancer stem cells. J. Genet Genom. 42, 355–371 (2015).

CAS  Google Scholar 

El Helou, R. et al. Brief reports: a distinct DNA methylation signature defines breast cancer stem cells and predicts cancer outcome. Stem Cells 32, 3031–3036 (2014).

CAS  Google Scholar 

Pathania, R. et al. DNMT1 is essential for mammary and cancer stem cell maintenance and tumorigenesis. Nat. Commun. 6, 6910 (2015).

CAS  Google Scholar 

Trowbridge, J. J. et al. Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. Genes Dev. 26, 344–349 (2012).

CAS  Google Scholar 

Liu, H. et al. Downregulation of FOXO3a by DNMT1 promotes breast cancer stem cell properties and tumorigenesis. Cell Death Differ. 27, 966–983 (2020).

CAS  Google Scholar 

Morita, R. et al. DNA methyltransferase 1 is essential for initiation of the colon cancers. Exp. Mol. Pathol. 94, 322–329 (2013).

CAS  Google Scholar 

Wei, Y. et al. The interaction between DNMT1 and high-mannose CD133 maintains the slow-cycling state and tumorigenic potential of glioma stem cell. Adv. Sci. 9, e2202216 (2022).

Google Scholar 

Vitale, I. et al. Apoptotic cell death in disease-current understanding of the NCCD 2023. Cell Death Differ. 30, 1097–1154 (2023).

Google Scholar 

Wang, Q. et al. DNMT1-mediated methylation of BEX1 regulates stemness and tumorigenicity in liver cancer. J. Hepatol. 75, 1142–1153 (2021).

CAS  Google Scholar 

Bruschi, M. et al. Loss of Apc rapidly impairs DNA methylation programs and cell fate decisions in Lgr5(+) intestinal stem cells. Cancer Res. 80, 2101–2113 (2020).

CAS  Google Scholar 

Lopez-Bertoni, H. et al. Sox2 induces glioblastoma cell stemness and tumor propagation by repressing TET2 and deregulating 5hmC and 5mC DNA modifications. Signal Transduct. Target Ther. 7, 37 (2022).

CAS  Google Scholar 

Gkountela, S. et al. Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. Cell 176, 98–112.e114 (2019).

CAS  Google Scholar 

Weissmann, S. et al. Landscape of TET2 mutations in acute myeloid leukemia. Leukemia 26, 934–942 (2012).

CAS  Google Scholar 

Tulstrup, M. et al. TET2 mutations are associated with hypermethylation at key regulatory enhancers in normal and malignant hematopoiesis. Nat. Commun. 12, 6061 (2021).

CAS  Google Scholar 

Shih, A. H. et al. Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer Cell 27, 502–515 (2015).

CAS  Google Scholar 

Asmar, F. et al. Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma. Haematologica 98, 1912–1920 (2013).

CAS  Google Scholar 

Guo, L. et al. Perturbing TET2 condensation promotes aberrant genome-wide DNA methylation and curtails leukaemia cell growth. Nat. Cell Biol. 26, 2154–2167 (2024).

CAS  Google Scholar 

Cimmino, L. et al. Restoration of TET2 function blocks aberrant self-renewal and leukemia progression. Cell 170, 1079–1095 e1020 (2017).

CAS  Google Scholar 

Li, Y. et al. TET2-mediated mRNA demethylation regulates leukemia stem cell homing and self-renewal. Cell Stem Cell 30, 1072–1090.e1010 (2023).

Google Scholar 

Raffel, S. et al. BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation. Nature 551, 384–388 (2017).

CAS  Google Scholar 

Pirozzi, C. J. & Yan, H. The implications of IDH mutations for cancer development and therapy. Nat. Rev. Clin. Oncol. 18, 645–661 (2021).

CAS  Google Scholar 

Figueroa, M. E. et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553–567 (2010).

CAS  Google Scholar 

Yao, Q. et al. IDH1 mutation diminishes aggressive phenotype in glioma stem cells. Int J. Oncol. 52, 270–278 (2018).

CAS  Google Scholar 

Tanabe, R. et al. PRRX1 induced by BMP signaling decreases tumorigenesis by epigenetically regulating glioma-initiating cell properties via DNA methyltransferase 3A. Mol. Oncol. 16, 269–288 (2022).

CAS  Google Scholar 

Kim, H. et al. Ten-eleven translocation protein 1 modulates medulloblastoma progression. Genome Biol. 22, 125 (2021).

CAS  Google Scholar 

Prasad, P. et al. Hypoxia-mediated epigenetic regulation of stemness in brain tumor cells. Stem Cells 35, 1468–1478 (2017).

CAS  Google Scholar 

Cimmino, L. et al. TET1 is a tumor suppressor of hematopoietic malignancy. Nat. Immunol. 16, 653–662 (2015).

CAS  Google Scholar 

Huang, H. et al. TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc. Natl. Acad. Sci. USA 110, 11994–11999 (2013).

CAS